CD123 Targeted Epigenetic Nanotherapy for Fusion Oncoprotein MLL‐AF9 Rearranged Acute Myeloid Leukemia in Preclinical and Patient Derived Xenograft Models

LSCs and stimulation of CD11b and Gr-1. In MLL-AF9 AML, C-Myb directly regulates EzH2 through promoter binding wherein si-EzH2@HNPs@ZW25 disrupt this functional crosstalk in AML revealingfuture translational potential of si-EzH2@HNPs@ZW25 as AML therapy.